On account of the superior effects on cardiovascular outcomes, GLP-1 receptor agonists and SGLT-2 inhibitors also gained much attention in aspect of retarding CAVD. This evidence concerns the gene SLC5A2 and congenital bilateral aplasia of vas deferens from CFTR mutation.